Subscription platform introduces AI-powered home management for reports, documents, valuables, service providers, repairs, warranties and more.

LocknCharge today announced the launch of ForwardPass, a self-service smart locker solution designed to help organizations automate the physical device workflows that are still often handled manually.

Did you know that you can now use Windows Update to reinstall your current Windows 11 version without losing data? Yes, this new feature lets you reinstall your current Windows 11 version using ...

Discover the 5 most common Mazda DTC codes and their fixes. We review P0171, P2096, P0126, P0300, and P0420 to help clear ...

Restart your Windows PC and then try using the MSINFO32.exe tool. This will kill all extra processes and reset any corrupt files or temporary settings that may be preventing the tool from running ...

Rowan University researchers have demonstrated a new method for repairing damage in advanced composite materials, offering a ...

Calhoun Community College is launching a new Diesel Technology Program this fall to prepare students for careers in one of the nation’s most in-demand trades, with registration now open. The program ...

Mind Technology Inc.’s latest earnings call struck a cautiously optimistic tone, balancing tangible operational gains with clear near‑term challenges. Management emphasized improved profitability ...

Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already includes 17 global phase 3 trials. But there’s one important missing piece. The New ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). And now, after meeting ...

Lead TroFuse-005 investigator Dr Domenica Lorusso of Humanitas University and Humanitas San Pio X in Milan, Italy. MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...